Prima BioMed Ltd (NASDAQ:PBMD) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Saturday. The brokerage presently has a $1.25 price target on the stock. Zacks Investment Research’s price target would indicate a potential upside of 19.05% from the company’s previous close. According to Zacks, […]
